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Abstract Purpose To correlate the expression of high-risk HPV E6 mRNA with pap smear,
colposcopy, and biopsy results in women with high grade squamous intraepithelial
lesion (HSIL).
Methods A cross-sectional study was performed on women referred for primary care
services after cytological diagnosis of HSIL. We evaluated the expression of E6/E7
mRNA of HPV types 16,18,31,33, and 45 and correlated the results with those of Pap
smear, colposcopy, and biopsy. For amplification/detection of mRNA E6 / E7 we used
NucliSENSEasyQ kit to detect HPV mRNA by polymerase chain reaction with primers/
probes for HPV types 16, 18, 31, 33, and 45.
Results Out of 128 valid tests, the results of 30 (23.4%) tests were negative and 98
(70%) tests were positive. Only one type of HPV was detected in 87.7% of the E6/E7
mRNA positive cases. HPV16 was detected in 61.2% of the cases, followed by HPV33
(26.5%), HPV31 (17.3%), HPV18 (10%), and HPV45 (4.08%). Pap smear tests revealed
that the E6/E7 test was positive in 107 (83.8%) women with atypical squamous cells –
high grade (ASC-H), HSIL, or higher. The E6/E7 test was positive in 69 (57.5%) specimens
presenting negative cytology results. When analyzing the association with colposcopy
results, the frequency of positive E6/E7 results increased with the severity of the injury,
ranging from 57.1% in women without colposcopy-detected injury to 86.5% in those
received
September 21, 2015
accepted
December 17, 2015
published online
March 21, 2016
DOI http://dx.doi.org/
10.1055/s-0036-1580713.
ISSN 0100-7203.
Copyright © 2016 by Thieme Publicações
Ltda, Rio de Janeiro, Brazil
Original Article
THIEME
154
Introduction
Frequent occurrence of cervical cancer has been reported
despite the use of cytological cervical screening (Papani-
colau test).1 Persistent infection by high-risk human pap-
illoma virus (HPV) is an important factor associated with
this neoplasia,2 which displays well-defined precursor
lesions that may become invasive after variable periods.
Thus, if the precursor lesions are detected at the initial or
pre-invasive stages, the progression of cervical cancer can
be interrupted.3
Oncotic cytology, introduced in 1943, is the most
widespread secondary prevention program ever intro-
duced for the screening of cervical cancer. However, the
sensitivity is limited and varies between 30 and 87% in
differentlaboratories.4 Recent studies defended its use in
conjunction with molecular tests to detect HPV DNA, with
a substantial increase in sensitivity and improved
reproducibility.5,6
Nevertheless, the detection of DNA only indicates the
presence of HPV7 and few infections are associated with
lesions that progress toward malignancy. For this to occur
there should be an overexpression of the E6 and E7 genes
from the genome of an integrated HPV. Thus, the E6 and E7
transcripts could be useful as markers of disease progres-
sion.8 The detection of the HPV E6/E7 messenger RNA
(mRNA) allows the monitoring of the oncogenic activity of
the virus, by detecting the active transcription of viral DNA.7
The levels of E6/E7 mRNA increase according to the
severity of the lesion.8,9 Thus, E6/E7 mRNA detection can
have a high prognostic value and can improve the specificity
and positive predictive value when compared with the HPV-
DNA test. According to a previous study, E6/E7 HPV-mRNA is
detected in more than 90% of the cervical intraepithelial
lesion CIN grades 2 and 3, or cervical cancer.7 Thus, the
objective of this study was to evaluate the expression of E6/
E7 mRNA of HPV types 16, 18, 31, 33, and 45 among women
with atypical cytological diagnosis, and correlate E6/E7
with higher levels of colposcopy findings. Of the 111 women who underwent biopsy
and E6/E7 testing, the E6/E7 test was positive in 84.7% of the women who presented
with lesions of cervical intraepithelial neoplasia (CIN) grade 2 or higher. Finally, 41.2% of
women with a negative biopsy presented a positive E6/E7 test.
Conclusions E6/E7 mRNA expression was higher in women with HSIL and CIN grade 2
or higher.
Resumo Objetivo Correlacionar a expressão mRNAE6/E7 do HPV de alto risco com os exames
de Papanicolau, colposcopia e biópsia em mulheres com lesão intraepitelial escamosa
de alto grau (HSIL).
Métodos Estudo transversal com mulheres encaminhadas aos serviços de atenção
primária com diagnóstico citológico de HSIL. Foi avaliada a expressão do mRNAE6/E7
dos tipos de HPV 16,18,31,33 e 45, correlacionando-se a expressão com os exames de
Papanicolau, colposcopia e biópsia. Para a amplificação/detecção demRNA de E6/E7
foi usado o kit NucliSENS EasyQ® HPV que detecta mRNA do HPV por meio da reação
em cadeia da polimerase com primers/probes HPV dos tipos 16, 18, 31, 33 e 45.
Resultados Foram obtidos 128 testes válidos. Destes: 30 (23,4%) foram negativos e
98 (70%) dos testes foram positivos. Foi encontrado apenas um tipo de HPV em 87,7%
dos positivos. O HPV16 foi o mais encontrado em 61,2%, seguido pelos HPV33 (26,5%);
HPV31 (17,34%); HPV 18 (10,0%) e HPV (45 4,0%). Quanto ao exame de Papanicolau, o
teste E6/E7 foi positivo em 107 (83,8%) das mulheres com ASC-H, HSIL ou superior,
enquanto em citologia negativa foi encontrado um resultado positivo em 69 (57,5%)
colposcopia. A frequência de teste E6/E7 positivo aumentou com a gravidade da lesão,
detectada na colposcopia variando de 57,1% em mulheres sem lesão identificada em
colposcopia até 86,5% naqueles com achado de colposcopia de grau maior. Das 111
mulheres que se submeteram a biópsia e o teste E6/E7, o teste foi positivo em 84,7%
das que apresentaram lesão igual ou superior a NIC 2 (neoplasia intraepitelial cervical) e
41,2% daqueles com biópsia negativa.
Conclusões A expressão de E6, E7 RNAm ocorreu commaior frequência em lesões de
alto grau citológica e em casos com biópsias de NIC2 ou maior.
Palavras-chave
► RNAm
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mRNA expression with the results of colposcopy-guided
biopsy.
Methods
A prospective cross-sectional study was conducted be-
tween July 2010 and November 2013. Women who at-
tended the Department of Pathology of the Lower Genital
Tract and Colposcopy of the Gynecology Department in
the Hospital das Clínicas of the Federal University of
Pernambuco (UFPE) - Brazil were included. All women
referred to primary care services were cytologically diag-
nosed with HSIL. After being informed about the objec-
tives of the study, women who agreed to participate in the
study signed an informed consent form and answered a
standard questionnaire. The study was approved by the
Ethics Committee in Research with Humans (CEPSH) of
the CCS (Health Sciences Center), UFPE.
The exclusion criteria were pregnancy, positive serology
for human immunodeficiency virus (HIV), and use of
immunosuppressants.
After the introduction of the speculum, a new ecto and
endocervical harvest was performed for smear cytology (CO)
by the conventional method, using an Ayre spatula and
cytobrush. The cytological report was based on the nomen-
clature of the Bethesda System.10
The brush used to collect samples for oncotic cytology,
was used to harvest new cervical material with the bristle
side placed in a 2 mL Eppendorf™ tube containing 1.5 mL of
buffered methanol, and the cervical samples were subse-
quently stored at -20°C until the HPV RNA extraction. The
amplification and detection of the E6/E7 mRNA was per-
formed with the NucliSENSEasyQ® HPV kit (BIOMÉRIEUX,
Marcy l'Etoile, France), using the polymerase chain reaction
(PCR) with primers/probes for HPV types 16, 18, 31, 33, and
45. In addition to the negative and positive controls, all
reactions were processed with the mRNA of the U1A gene
as an internal control, to ensure the integrity of the RNA and
the reagents. The preparation of the reagent mix and addi-
tion of the samples followed the protocol recommended by
themanufacturer. The protocolwas concluded by placing the
plate in the NucliSENSEasyQ® equipment for the mRNA
detection and amplification.
After collecting the materials for oncotic cytology and the
E6/E7 test, colposcopy examination was performed and
findings were described according to the nomenclature of
the International Federation of Colposcopy and Cervical
Pathology.11 In cases of suspected lesion, the biopsy was
Table 1 E6/E7 test results according to the epidemiological characteristics of women referred to a primary care service with Pap
test compatible with high-grade squamous intraepithelial lesion (HSIL)
Variables Test Result p-value
Positive
Mean  SD
Negative
Mean  SD
Age 35.3  11.0 41.9  11.8 0.00
Age, first sexual intercourse 16.0  2.9 17.3  4.3 0.06
Number of pregnancies 3.4  2.8 4.5  3.4 0.09
Number of partners 3.9  2.8 3.3  2.7 0.29
Age at first delivery 17.5  4.8 20.0  4.5 0.01
n (%) n (%)
Smoking
Never 69 (70.4) 21 (70.0) 0.73
Yes 23 (23.5) 6 (20.0)
Ex-smokers 6 (6.1) 3 (10.0)
Alcohol
Abstinent 52 (53.1) 21 (70.0) 0.1
Not totally abstinent 46 (46.9) 9 (30.0)
Number of preventive measures 1.5  1.2 1.2  1.3 0.19
Use of condom
Never Used 24 (24.5) 12 (40.0) 0.16
Sometimes 31 (31.6) 9 (30.0)
Always 10 (10.2) 0
Already used, but not currently 33 (33.7) 9 (30.0)
Abbreviation: SD, standard deviation.
, t-test, , chi-square test, , Mann-Whitney Test.
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performed with Gaylor-Medina forceps. The fragments were
placed in a vial with 10% buffered formalin and sent for
histopathological examination.
In the pathology laboratory, the fragments were processed
and embedded in paraffin and subsequently sliced to obtain 5-
µm-sections, which were stained with hematoxylin-eosin and
analyzed by optical microscopy. The reports were in accordance
with the international nomenclature of pathology for cervical
intraepithelial neoplasia and cervical cancer.12
The responses to the questionnaire and the results of the
examinations and procedures were entered in the EPI-INFO
program. The chi-square test and the chi-square test for
trend were used to compare categorical variables and the
t-test for comparison of means. The Mann-Whitney test was
used for the variables that did not present a normal distri-
bution. The differences were considered statistically signifi-
cant when p< 0.05. All analyzes were performed using the
Stata (version 10.1) statistical software.
Results
Samples were obtained from the 140 women presenting
with HSIL to detect E6/E7 mRNA of HPV types 16, 18, 31, 33,
and 45. Out of all cases, 8.6% (12/140) presented invalid data,
21.4% (30/140) were negative, and 70% (98/140) positive.
Among the 128 valid tests, 23.4% (30/128) were negative
for E6/E7 mRNA. Among the 98 positive cases, only one type
of HPV was detected in 87.7% of the samples (86/98).
The comparison of socio-demographic characteristics
between the patients with negative and positive results
showed no significant difference (►Table 1).
HPV16 was the most common type detected, 61.2% (60/
98), followed byHPV33, 26.5% (26/98), HPV31, 17.3% (17/98),
HPV18, 5.1% (5/98), and HPV45, 4.1% (4/98).
Among the 12.2% (12/98) cases presenting multiple in-
fections, the most frequently detected type was also HPV16
(83.3%), followed by HPV33 (75%), HPV45 (25%), HPV31
(16.7%), and HPV18 (8.3%).
The HPV18 type was detected in one biopsy displaying
adenocarcinoma, in the only cytology that displayed adeno-
carcinoma in-situ (AIS), and in one of the two cytology with
adenocarcinoma; in the other cytology, HPV16was identified.
When the cytology was repeated, the following results
were observed: unsatisfactory, two (1.4%); negative, 23
(16.4%); atypical squamous cells of undetermined signifi-
cance (ASC-US), eight (5.7%); low-grade squamous intra-
epithelial lesion (LSIL), 23 (16.4%); atypical squamous cells
in which HSIL cannot be excluded (ASC-H), 6 (4.3%); HSIL, 70
(50.0%); HSILwithout exclusion ofmicroinvasion, one (0.7%);
squamous cancer, four (2.9%); atypical squamous cells, one
(0.7%); adenocarcinoma, two (1.4%).
The E6/E7 test was positive in 83.8% of women with ASC-
H, HSIL, or greater, while, in women presenting a negative
cytology, E6/E7 test was positive in 57.9% of the cases
(►Table 2).
Of the 140 colposcopy examinations, 11.4% of the cases
presented no lesion and 6.3% presented unspecific or mis-
cellaneous changes. Abnormal low-grade colposcopy find-
ings were identified in 42.9% of the cases and higher
gradecolposcopy findings in 39.3%. The squamocolumnar
junction was not visualized in 37.9% of the cases.
Among the 128womenwhowere subjected to colposcopy
and for which the E6/E7 test was valid, 82% presented
abnormal colposcopy findings and 18% showed no lesion
or nonspecific lesion. The frequency of E6/E7 positivity
ranged from 57.1% in women without colposcopy-detected
lesions and up to 86.5% in those with higher-grade colposco-
py-detected lesions.
Histopathological examination of 124 biopsy samples
showed the following results: negative, 13.6%; CIN1, 15.7%;
CIN2, 19.3%; CIN3, 35.7%; microinvasion, 0.7%; squamous
cancer, 0.7%; adenocarcinoma, 0.7%; CIN ungraded, 1.4%; and
inadequate sample, 0.7%.
Among the 111 women who underwent a biopsy and
presented a valid E6/E7 test, the E6/E7 test was positive in
84.72% of the women presenting with neoplasia equal or
more serious than CIN2 and in 41.18% of women present-
ing with negative biopsy. The sensitivity of the test for
CIN2 or higher was 84.7%, while the specificity was 30.8%.
The positive predictive value was 69.3%. The negative
Table 2 Relationship between colposcopy-detected findings and positivity of HPV E6/E7mRNA test in women referred to a primary
care service with a Pap test compatible with high-grade squamous intraepithelial lesion (HSIL)
Cytology Test Result Total
Positive Negative
N % N % N %
Negative 11 57.8 8 42.1 19 15.4
ASC-US / LSIL 22 73.3 8 26.6 30 24.3
ASC-H /  HSIL 62 83.7 12 16.2 74 60.1
Total 95 77.2 28 22.7 123 100.0
Abbreviation: ASC-H, atypical squamous cells of undetermined significance in which high-grade squamous intraepithelial lesion cannot be excluded;
ASC-US, atypical squamous cells of undetermined significance possibly non-neoplastic; HSIL, high-grade squamous intraepithelial lesion; LSIL, low-
grade squamous intraepithelial lesion.
P value ¼ 0.02127; x2 trend value ¼ 5.30481.
Note: Two results of unsatisfactory cytology and three of glandular lesions were not included. Additionally, invalid E6/E7 tests were not included.
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predictive value was 52.2%, and the accuracy was 65.7%
(►Table 3).
Discussion
The E6/E7 mRNA test of HPV types 16, 18, 31, 33, and 45 was
positive in 76% of women who presented with a cytological
diagnosis of HSIL and in 83% of the women whose diagnosis
was confirmed by new cytology tests performed for the
study. There was an increase in the percentage of positivity
proportional to the grading of the cytological and histopath-
ological changes. HPV16wasdetectedwith higher frequency,
followed by HPV 33, 31, 18, and 45. Such findings are similar
to those of Dixon et al,13who observed positive results in 80%
of HSIL samples. The cytological, colposcopic, and histologi-
cal correlations confirmed the observations of other
authors.8,9,14
Among the cases with negative cytology, ASC-H cases had
57.9% with an E6/E7 positive test, while the ≥HSIL cases had
83.8%. Cases in which the cytology was negative and the E6/
E7 test was positive suggest the possibility of false negative
cytology or viral integration without morphological le-
sions.15,16 According to Li and Kristensen,7 when the cytolo-
gy examination reveals negative result and the E6/E7 test is
positive, one could consider a latent infection. Negative E6/
E7 tests observed in women with high-grade colpocytologic
findings could be due to the presence of other types of HPV,
not screened in this study.7 However, previous studies
suggest caution in these cases due to the higher risk of other
important findings in the follow-up.17
The HPV E6/E7 mRNA test was positive in 85% of the
biopsieswith CIN2 or higher, in agreementwith the variation
described by others, who detected HPV E6/E7 mRNA be-
tween 63% and 92% of CIN2, 3, or cervical cancer.7,18,19 Such
findings demonstrated an interesting sensitivity for the
identification of high-grade and invasive lesions and are in
agreement with the literature.20
In this study, HPV16 was identified as the most frequent
type (61%), in agreement with other studies, taking into
account the regional variability of other types.21–26 The
HPV18 type, related with glandular lesions,27–29 was associ-
ated with confirmed adenocarcinoma.
The performance of the test was studied in relation to
CIN2 or higher grade, considering the histopathologic diag-
nosis as the gold standard.30,31 The sensitivity of the E6/E7
test, 84% for CIN2/3, was greater than that observed by
Jeantet et al,32 who determined a 73.6% sensitivity for
CIN2 and 82.2% for CIN3. These numbers were lower than
that obtained by Pierry et al,33 who observed a 89% sensitiv-
ity for CIN2 and 100% for CIN3. These numbers led some
researchers to suggest the use of the E6/E7 test as a screening
test in cases with abnormal cytology or HPV-DNA tests.34
Given the results, one can conclude that the expression of
E6/E7 mRNA was observed the most among patients with
HSIL and CIN2 or higher grades in the biopsy, which suggests
an important correlation that could be inferred as a prog-
nostic factor. Nevertheless, despite the tendency to use E6/E7
mRNA screening test due to its prognostic value, new and
more well-designed studies are needed to confirm the
effectiveness of this test.
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